Journal Mobile Options
Table of Contents
Vol. 68, Suppl. 1, 2005
Issue release date: April 2005
Section title: Paper
Oncology 2005;68(suppl 1):22–32
(DOI:10.1159/000083130)

Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life

Cortesi E. · Gascón P. · Henry D. · Littlewood T. · Milroy R. · Pronzato P. · Reinhardt U. · Shasha D. · Thatcher N. · Wilkinson P.
aDipartimento Medicina Sperimentale e Patologia, Università di Roma, Rome, Italy; bHospital Clinic, Barcelona, Spain; cPennsylvania Hospital, Philadelphia, Pa., USA; dJohn Radcliffe Hospital, Oxford, UK; eStobhill Hospital, Glasgow, UK; fOspedale S. Andrea, La Spezia, Italy; gKlinik Bayreuth, Bayreuth, Germany; hBeth Israel Medical Center, New York, N.Y., USA; iChristie Hospital NHS Trust, Manchester, UK

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 4/11/2005

Number of Print Pages: 11
Number of Figures: 5
Number of Tables: 2

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

The introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level <12 g/dl) cancer patients undergoing chemotherapy. Increased Hb improves patients’ energy level and their ability to perform the activities of daily living, as well as their overall quality of life (QOL). These findings are independent of tumor type and disease status and are comparable in patients receiving nonplatinum- and platinum-based chemotherapeutic regimens. Furthermore, more than a decade of use in clinical trials and by physicians in routine clinical practice has demonstrated that epoetin alfa is safe and well tolerated when used to treat cancer patients with anemia. The availability of epoetin alfa as an alternative to transfusion has changed practices in anemia management; physicians can now treat anemia with the goal of achieving adequate Hb levels to relieve anemia-related fatigue, a major symptom contributing to decreased QOL in cancer patients. Incremental benefit analysis has shown that increasing Hb level from 11 g/dl to 12 g/dl yields the greatest improvement in QOL per 1 g/dl increase in Hb. The demonstrated efficacy of epoetin alfa for increasing Hb levels and improving patient QOL have made this agent a rationale choice for management of cancer-related anemia. Ongoing research will continue to provide new insights into best management of anemia with epoetin alfa in cancer patients.


  

Author Contacts

Pere Gascón, MD, PhD
Hospital Clinic, Servei d’Oncologia Medica
Villarroel 170, esc. 2, planta 5
ES–08036 Barcelona (Spain)
Tel. +34 93 227 5402, Fax +34 93 227 5402, E-Mail gascon@clinic.ub.es

  

Article Information

Number of Print Pages : 11
Number of Figures : 5, Number of Tables : 2, Number of References : 40

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 68, No. Suppl. 1, Year 2005 (Cover Date: Released April 2005)

Journal Editor: D.L. Trump, Buffalo, N.Y.
ISSN: 0030–2414 (print), 1423–0232 (Online)

For additional information: http://www.karger.com/ocl


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 4/11/2005

Number of Print Pages: 11
Number of Figures: 5
Number of Tables: 2

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.